Exploring metabolic dysfunction in chronic kidney disease

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Slee, Adrian D ^a  

^a UNIVERSITY OF LINCOLN   (United Kingdom)

Author keywords

Cachexia; Cardiovascular disease; Chronic kidney disease

Indexed keywords

ADIPONECTIN; ALBUMIN; ALDOSTERONE; ANGIOTENSIN II; C REACTIVE PROTEIN; GHRELIN; GROWTH HORMONE; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR; VITAMIN D;

ANOREXIA; CACHEXIA; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84862225648     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-36     Document Type: Review

References (148)

1. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification. Levey AS, Coresh J, Balk E, et al. Ann Intern Med 2003 139 137 147 12859163
2. Slowing progression along the renal disease continuum. Kopyt NP, JAOA 2005 105 4 207 215 15928338 (Pubitemid 40840098)
3. Chronic kidney disease and end-stage renal diseasea review produced to contribute to the report the status of health in the European union: towards a healthier Europe. aZoccali C, Kramer A, Jager KJ, NDT Plus 2010 3 213 224 10.1093/ndtplus/sfp127
4. Epidemiology of CKD in Europe: an uncertain scenario. bZoccali C, Kramer A, Jager KJ, Nephrol Dial Transplant 2010 25 1731 1733 10.1093/ndt/gfq250 20501467
5. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Kundhal K, Lok CE, Nephron Clin Pract 2005 101 47 52 10.1159/000086221 (Pubitemid 41208890)
6. Chronic kidney disease and mortality risk: a systematic review. Tonelli M, Wiebe N, Culleton B, et al. J Am Soc Nephrol 2006 17 2034 2047 10.1681/ASN.2005101085 16738019 (Pubitemid 44036188)
7. The association of renal impairment and all-cause and cardiovascular disease mortality. Nitsch D, Lawlor DA, Patel R, Carson C, Shah Ebrahim S, Nephrol Dial Transplant 2010 25 1191 1199 10.1093/ndt/gfp607 19948872
8. The scope of coronary heart disease in patients with chronic kidney disease. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, DeMattos AM, Iskandrian AE, J Am Coll Cardiol 2009 53 2129 2140 10.1016/j.jacc.2009.02.047 19497438
9. Epidemiology of cardiovascular risk in patients with chronic kidney disease. Locatelli F, Pozzoni P, Tentori F, Del Vecchio L, Nephrol Dial Transplant 2003 18 Suppl 7 vii2-vii9 12953023 (Pubitemid 37098602)
10. Optimizing bone health in chronic kidney disease. Pelletier S, Chapurlat R, Maturitas 2010 65 325 333 10.1016/j.maturitas.2009.12.021 20092971
11. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: improving global outcomes (KDIGO). Moe S, Drüeke T, Cunningham J, et al. Kidney Int 2006 69 1945 1953 10.1038/sj.ki.5000414 16641930 (Pubitemid 43924257)
12. Mechanisms causing loss of lean body mass in kidney disease. Mitch WE, Am J Clin Nutr 1998 67 359 366 9497177 (Pubitemid 28110454)
13. Skeletal muscle dysfunction in chronic renal failure: effects of exercise. Adams GR, Vaziri ND, Am J Physiol Renal Physiol 2006 290 753 761
14. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Vaziri ND, Am J Physiol Renal Physiol 2006 290 262 272 10.1152/ajprenal.00099.2005 (Pubitemid 43724980)
15. Insulin resistance and protein energy metabolism in patients with adVanced chronic kidney disease. Siew ED, Ikizler TA, Semin Dial 2010 23 4 378 382 10.1111/j.1525-139X.2010.00763.x 20701717
16. Impact of dyslipidemia in end-stage renal disease. Prichard SS, J Am Soc Nephrol 2003 14 315 320 10.1097/01.ASN.0000081698.10331.83
17. Anemia: The point of convergence or divergence for kidney disease and heart failure. Kazory A, Ross EA, J Am Coll Cardiol 2009 53 639 647 10.1016/j.jacc.2008.10.046 19232895
18. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Levin A, Li YC, Kidney Int 2005 68 1973 1981 10.1111/j.1523-1755.2005.00651.x 16221197 (Pubitemid 43117772)
19. Vascular calcification: the killer of patients with chronic kidney disease. Mizobuchi M, Towler D, Slatopolsky E, J Am Soc Nephrol 2009 20 1453 1464 10.1681/ASN.2008070692 19478096
20. Review of muscle wasting associated with chronic kidney disease. Workeneh BT, Mitch WE, Am J Clin Nutr 2010 91 1128S 1132S 10.3945/ajcn.2010.28608B 20181807
21. Inflammation and cachexia in chronic kidney disease. Cheung WW, Paik KH, Mak RH, Pediatr Nephrol 2010 25 711 724 10.1007/s00467-009-1427-z 20111974
22. Cardiac cachexia a syndrome with impaired survival and immune and neuroendocrine activation. Anker SD, Coats AJS, Chest 1999 115 836 847 10.1378/chest.115.3.836 10084500 (Pubitemid 29129969)
23. Cachexia. Kotler D, Ann Intern Med 2000 133 622 634 11033592
24. Peripheral muscle wasting in chronic obstructive pulmonary disease. Debigaré R, Côté CH, Maltais F, Am J Respir Crit Care Med 2001 164 1712 1717 11719314
25. Neural control of the anorexia-cachexia syndrome. Laviano A, Inui A, Marks DL, et al. Am J Physiol Endocrinol Metab 2008 295 1000 1008 10.1152/ajpendo.90252.2008
26. Adipokines and gut hormones in end-stage renal disease. Mak RH, Cheung W, Perit Dial Int 2007 27 Suppl.2 298 S302
27. The growth hormone-insulin-like growth factor-I axis in chronic kidney disease. Mak RH, Cheung WW, Roberts CT, Growth Horm IGF Res 2008 18 17 25 10.1016/j.ghir.2007.07.009 17826224 (Pubitemid 351228810)
28. Consensus report: expert working group report on nutrition in adult patients with renal insufficiency (part 1 of 2). aToigo G, Aparicio M, Attman P-O, et al. Clin Nutr 2000 19 3 197 207 10.1054/clnu.1999.0130 10895111 (Pubitemid 30599310)
29. Consensus report: expert working group report on nutrition in adult patients with renal insufficiency (part 2 of 2). bToigo G, Aparicio M, Attman P-O, et al. Clin Nutr 2000 19(4 281 291
30. Renal failure-measuring the glomerular filtration rate. Thomas C, Thomas L, Dtsch Arztebl Int 2009 106 51-52 849 854 20062583
31. Monitoring renal function: measured and estimated glomerular filtration rates-a review. Salgado JV, Neves FA, Bastos MG, et al. Brax J Med Biol Res 2010 43 6 528 536 10.1590/S0100-879X2010007500040
32. Comparative performance of the CKD epidemiology collaboration (CKD-EPI) and the modification of diet in renal disease (MDRD) study equations for estimating GFR levels above 60mL/min/1.73m2. aStevens LA, Schmid CH, Greene T, et al. Am J Kidney Dis 2010 56 3 486 495 10.1053/j.ajkd.2010.03.026 20557989
33. AdVance in glomerular filtration rate estimating equations. bStevens LA, Padala S, Levey AS, Curr Opin Nephrol Hypertens 2010 19 3 298 307
34. Should eGFR and albuminuria be added to the framingham risk score? chronic kidney disease and cardiovascular disease risk prediction. Chang A, Kramer H, Nephron Clin Pract 2011 119 2 171 c177 10.1159/000325669 21811078
35. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk-a cohort study. Clase CM, Gao P, Tobe SW, et al. Ann Intern Med 2011 154 310 318 21357908
36. Chronic kidney disease in older people: a cause for concern? Roderick PJ, Nephrol Dial Transplant 2011 26 3083 3086 10.1093/ndt/gfr515 21917730
37. The conundrum of chronic kidney disease classification and end-stage renal risk prediction in the elderly - what is the right approach? Hallan SI, Orth SR, Nephron Clin Pract 2010 116 307 c316 10.1159/000319166 20664285
38. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Thomas G, Sehgal AR, Kashyap SR, et al. CJASN 2011 6 10 2364 2373 21852664
39. Renal manifestations in the metabolic syndrome. Locatelli F, Pozzoni P, Del Vecchio L, J Ann Soc Nephrol 2006 17 81 85 10.1681/ASN.2005121332
40. The role of sympathetic nervous system activity in renal injury and end-stage renal disease. Masuo K, Lambert GW, Esler MD, et al. Hypertens Res 2010 33 521 528 10.1038/hr.2010.35 20339374
41. The emerging clinical implication of the role of aldosterone in the metabolic syndrome and resistant hypertension. Sowers JR, Whaley-Connell A, Epstein M, Ann Intern Med 2009 150 776 783 19487712
42. Adipose tissue in renal disease: clinical significance and prognostic implications. Iglesias P, Diez JJ, Nephrol Dial Transplant 2010 25 7 2066 2077 10.1093/ndt/gfq246 20466661
43. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Wang M, Nutr Metab 2005 2 3 10.1186/1743-7075-2-3 (Pubitemid 40397809)
44. Mechanisms of endothelial dysfunction in chronic kidney disease. Malyszko J, Clinica Chimica Acta 2010 411 1412 1420 10.1016/j.cca.2010.06.019
45. Impairment of small intestinal protein assimilation in patients with end-stage renal disease: extending the malnutrition-inflammation-atherosclerosis concept. Bammens B, Evenepoel P, Verberke K, Vanrenterghem Y, Am J Clin Nutr 2004 80 1536 1543 15585765 (Pubitemid 41103850)
46. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Kobayashi S, Maejima S, Ikeda T, Nagase M, Nephrol Dial Transplant 2000 15 65 70 11261709 (Pubitemid 30037932)
47. The stressful condition as a nutritionally dependent adaptive dichotomy. Ingenbleek Y, Bernstein L, Nutrition 1999 15 305 320 10.1016/S0899-9007(99) 00009-X 10319365 (Pubitemid 29201099)
48. Acute phase reaction and acute phase proteins. Gruys E, Toussaint MJM, Niewold TA, Koopmans SJ, J Zheijang Univ Sci 2005 6B 11 1045 1056 10.1631/jzus.2005.B1045 (Pubitemid 43083934)
49. Endocrine dysfunction in chronic renal failure. Mooradian AD, Morley JE, Arch Intern Med 1984 144 2 351 353 10.1001/archinte.1984.00350140175024 6365009 (Pubitemid 14186829)
50. Oxidative stress and gene expression in sepsis. Macdonald J, Galley HF, Webster NR, Br J Anaesth 2003 90 2 221 232 10.1093/bja/aeg034 12538380 (Pubitemid 36181968)
51. C-reactive protein and myocardial infarction. Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, Tracy RP, J Clin Epidemiol 2002 55 445 451 10.1016/S0895-4356(01)00502-9 12007546 (Pubitemid 34462239)
52. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. Koenig W, Int J Cardiol 2005 98 199 206 10.1016/j.ijcard. 2004.05.019 15686768 (Pubitemid 40431164)
53. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen. Wilson AM, Ryan MC, Boyle AJ, Int J Cardiol 2006 106 291 297 10.1016/j.ijcard.2005.01.068 16337036 (Pubitemid 41766629)
54. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: a 5-year prospective study. Akdag I, Yilmaz Y, Kahvecioglu S, et al. Nephron Clin Pract 2008 108 2 99 105 10.1159/000113526 (Pubitemid 351346932)
55. C-reactive protein in end-stage renal disease: are there reasons to measure it? Stenvinkel P, Lindholm B, Blood Purif 2005 23 72 78 10.1159/000082014 15627740 (Pubitemid 40082247)
56. Serum albumin, c-reactive protein, interleukin 6 and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Honda H, Qureshi AR, Heimbürger O, et al. Am J Kidney Dis 2006 47 1 139 148 10.1053/j.ajkd.2005.09.014 16377395 (Pubitemid 41828276)
57. The ubiquitous interleukin-6: a time for reappraisal. Fisman EZ, Tenenbaum A, Cardiovasc Diabetol 2010 9 62 10.1186/1475-2840-9-62 20937099
58. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Thayer JF, Yamamoto SS, Brosschot JF, Int J Cardiol 2010 141 122 131 10.1016/j.ijcard.2009.09.543 19910061
59. Cachexia: pathophysiology and clinical releVance. Morley JE, Thomas DR, Wilson MMG, Am J Clin Nutr 2006 83 735 743 16600922 (Pubitemid 44713134)
60. Wasting in chronic kidney disease. Mak RH, Ikizler AT, Kovesdy CP, et al. J Cachexia Sarcopenia Muscle 2011 2 9 25 21475675
61. Ghrelin in chronic kidney disease. Cheung WW, Mak RH, Int J Pept 2010
62. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Carrero JJ, Qureshi AR, Axelsson J, et al. Am J Clin Nutr 2007 85 3 695 701 17344489 (Pubitemid 46393499)
63. Resting energy expenditure of chronic kidney disease patients: influence of renal function and subclinical inflammation. Avesani CM, Draibe SA, Kamimura MA, Basile FA, Colugnati MS, Cuppari L, Am J Kid Dis 2004 44 6 1008 1016 10.1053/j.ajkd.2004.08.023 15558521 (Pubitemid 39556480)
64. Association between body mass and mortality in maintenance hemodialysis patients. Yen T-H, Lin J-L, Lin-Tan D-T, Hsu C-W, Ther Aphre Dial 2010 14 4 400 408 10.1111/j.1744-9987.2010.00818.x
65. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Gibney J, Healy M-L, Sönksen PH, Endocr Revs 2007 28 6 603 624 10.1210/er.2006-0052 (Pubitemid 47610444)
66. Regulation of muscle mass by growth hormone and IGF-1. Velloso CP, Br J Pharmacol 2008 154 557 568 10.1038/bjp.2008.153 18500379 (Pubitemid 351744951)
67. Exercise effects on muscle insulin signaling and action, invited review: autocrine/paracrine IGF-1 and skeletal muscle adaptation. Adams GR, J Appl Physiol 2002 93 1159 1167 12183514 (Pubitemid 34919690)
68. Response of IGF-1 to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Donahue SP, Phillips LS, Am J Clin Nutr 1989 50 962 969 2816803 (Pubitemid 19280019)
69. New concepts: growth hormone, insulin-like growth factor-I and the kidney. Rabkin R, Schaefer F, Growth Horm IGF Res 2004 14 4 270 276 10.1016/j.ghir.2004.02.001 15231295 (Pubitemid 38878052)
70. Growth hormone axis in chronic kidney disease. Mahesh S, Kaskel F, Paediatr Nephrol 2008 23 41 48 (Pubitemid 350245970)
71. Hypothalamic-pituitary-adrenal axis, neuro-endocrine factors and stress. Tsigos C, Chrousos GP, J Psychosom Res 2002 53 865 871 10.1016/S0022-3999(02) 00429-4 12377295 (Pubitemid 35282615)
72. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. Sun DF, Zheng Z, Tummala P, Oh J, Schaefer F, Rabkin R, J Am Soc Nephrol 2004 15 2630 2636 10.1097/01.ASN.0000139492.36400.6C 15466267 (Pubitemid 41103369)
73. Alteration of somatotropic function by proinflammatory cytokines. Frost RA, Lang CH, J Anim Sci 2004 82 100 109
74. Insulin resistance in critically ill patients with acute renal failure. Basi S, Pupim LB, Simmons EM, et al. Am J Physiol Renal Physiol 2005 289 259 264 10.1152/ajprenal.00002.2005 (Pubitemid 41003654)
75. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ, Nephrol Dial Transplant 2007 22 9 2554 2562 10.1093/ndt/gfm204 17438006 (Pubitemid 47365520)
76. Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients. Abdulle AM, Gillett MP, Abouchacra S, et al. Mol Cell Biochem 2007 302 1-2 195 201 17387582 (Pubitemid 47202335)
77. A super-agonist of growth hormone-releasing hormone causes rapid improvement of nutritional status in patients with chronic kidney disease. Niemczyk S, Sikorska H, Wiecek A, et al. Kidney Int 2010 77 5 450 458 10.1038/ki.2009.480 20016461
78. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Kim S, Iwao H, Pharmacol Rev 2000 52 1 11 34 10699153 (Pubitemid 30127593)
79. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Carey RM, Siragy HM, Hypertension 2000 35 part 155 163 10642292 (Pubitemid 30054167)
80. Newly recognised components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Carey RM, Siragy HM, Endocr Rev 2003 24 3 261 271 10.1210/er.2003-0001 12788798 (Pubitemid 36733542)
81. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Lastra G, Dhuper S, Johnson MS, Sowers JR, Nat Rev Cardiol 2010 7 577 584 10.1038/nrcardio.2010.123 20697411
82. Mineralocorticoid Receptor Blockers and Chronic Kidney Disease. Jain G, Campbell RD, Warnock DG, Clin J Am Soc Nephrol 2009 4 1685 1691 10.2215/CJN.01340209 19729430
83. Inflammation in early atherogenesis: impact of ACE inhibition. De Caterina R, Manes C, Eur Heart J Suppl 2003 5 Suppl. A 15 A24
84. Reactive oxygen species impair sympathetic vasoregulation in skeletal muscle in angiotensin II-dependent hypertension. Zhao W, Swanson SA, Ye J, et al. Hypertension 2006 48 637 643 10.1161/01.HYP.0000240347.51386.ea 16940212 (Pubitemid 44848210)
85. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Casas JP, Chua W, Loukogeorgakis S, et al. Lancet 2005 366 9502 2026 2033 10.1016/S0140-6736(05)67814-2 16338452 (Pubitemid 41773378)
86. Reno-protective effects of renin-angiotensin system blockaDe in type 2 diabetic patients: a systematic review and network meta-analysis. Vejakama P, Thakkinstian A, Lertrattananon D, et al. Diabetologia 2012 55 566 578 10.1007/s00125-011-2398-8 22189484
87. Dual renin-angiotensin-aldosterone system blockaDe for diabetic kidney disease. Pichler RH, De Boer IH, Curr Diab Rep 2010 10 4 297 305 10.1007/s11892-010-0126-2 20532701
88. Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people? Burton LA, McMurdo MET, Struthers AD, Clin Endocrinol 2011 75 725 729 10.1111/j.1365-2265.2011.04148.x
89. Selective angiotensin II receptor antagonism reduces insulin resistance in obese zucker rats. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M, Hypertension 2001 38 884 890 10.1161/hy1101.092970 11641303 (Pubitemid 34258687)
90. Angiotensin II-induced insulin resistance and protein tyrosine phosphatases. Marrero MB, Fulton D, Stepp D, Stern DM, Arterioscler Thromb Vasc Biol 2004 24 2009 2013 10.1161/01.ATV.0000140059.04717.f3 15271787 (Pubitemid 39482422)
91. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. Wei Y, Sowers JR, Nistala R, et al. J Biol Chem 2006 281 46 35137 35146 10.1074/jbc.M601320200 16982630 (Pubitemid 46036553)
92. Chronic ANG II infusion increases plasma triglyceriDe level by stimulating hepatic triglyceriDe production in rats. Ran J, Hirano T, Adachi M, Am J Physiol Endocrinol Metab 2004 287 955 961 10.1152/ajpendo.00199.2004 (Pubitemid 39382933)
93. Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Kouyama R, Suganami T, Nishida J, et al. Endocrinology 2005 146 3481 3489 10.1210/en.2005-0003 15878965 (Pubitemid 41065022)
94. Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Prasad A, Quyyumi AA, Circulation 2004 110 1507 1512 10.1161/01.CIR.0000141736.76561.78 15364819 (Pubitemid 39238031)
95. Short-term administration of an angiotensin-receptor antagonist in patients with impaired fasting glucose improves insulin sensitivity and increases free IGF-1. Zandbergen AMZ, Lamberts SW, Janssen JAMJL, Bootsma AH, Eur J Endocrinol 2006 155 293 296 10.1530/eje.1.02219 16868143 (Pubitemid 44269446)
96. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade. De Vinuesa SG, Goicoechea M, Kanter J, et al. J Am Soc Nephrol 2006 17 206 212 10.1681/ASN.2006080916 (Pubitemid 44865250)
97. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, Delafontaine P, Endocrinology 2001 142 4 1489 1496 10.1210/en.142.4.1489 11250929 (Pubitemid 32299677)
98. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. Song Y-H, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P, J Clin Invest 2005 115 451 458 15650772 (Pubitemid 40385487)
99. Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat. Burniston JG, Saini A, Tan L-B, Goldspink DF, Exp Physiol 2005 90 5 755 761 10.1113/expphysiol.2005.030908 15987733 (Pubitemid 41406064)
100. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Rajala MW, Scherer PE, Endocrinology 2003 144 9 3765 3773 10.1210/en.2003-0580 12933646 (Pubitemid 37088727)
101. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Unger RH, Endocrinology 2003 144 12 5159 5165 10.1210/en.2003-0870 12960011 (Pubitemid 37476041)
102. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Meier U, Gressner AM, Clin Chem 2004 50 9 1511 1525 10.1373/clinchem.2004.032482 15265818 (Pubitemid 39121218)
103. Role of adipose tissue as an inflammatory organ in human diseases. Schäffler A, Müller-Ladner U, Schölmerich J, Büchler C, Endocr Rev 2006 27 5 449 467 10.1210/er.2005-0022 16684901 (Pubitemid 44213227)
104. Adiposity and cardiovascular disorders. Katagiri H, Yamada T, Oka Y, Circ Res 2007 101 27 39 10.1161/CIRCRESAHA.107.151621 17615379 (Pubitemid 47094621)
105. Spectrum of renal diseases associated with extreme forms of insulin resistance. Musso C, Javor E, Cochran E, Balow JE, Gorden P, Clin J Am Soc Nephrol 2006 1 616 622 10.2215/CJN.01271005 17699267
106. Systemic low-graDe inflammation is related to both circulating and adipose tissue TNF and adipose tissue TNF, leptin and IL-6 levels in obese women. Maachi M, Piéroni L, Bruckert E, et al. Int J Ob 2004 29 993 997 (Pubitemid 38998704)
107. Does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes. Tataranni PA, Ortega E, Diabetes 2005 54 917 927 10.2337/diabetes.54.4.917 15793228 (Pubitemid 40446304)
108. The adipocyte-myocyte axis in insulin resistance. Sell H, Dietze-Schroeder D, Eckel J, Trends Endocrinol Metab 2006 17 10 416 422 10.1016/j.tem.2006.10.010 17084639 (Pubitemid 44780130)
109. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Axelsson J, Qureshi AR, Suliman ME, et al. Am J Clin Nutr 2004 80 1222 1229 15531669 (Pubitemid 41350682)
110. Role of leptin in the activation of immune cells. Fernández-Riejos P, Najib S, Santos-Alvarez J, et al. Mediators Inflamm 2010 2010 568343 20368778
111. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K, J Clin Invest 2006 116 7 1784 1792 10.1172/JCI29126 16823476 (Pubitemid 44033298)
112. Adiponectin concentration are influenced by renal function and diabetes duration in pima indians with type 2 diabetes. Looker HC, Krakoff J, Funahashi T, et al. J Clin Endocrinol Metab 2004 89 4010 4017 10.1210/jc.2003-031916 15292342 (Pubitemid 39071508)
113. Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D, Nephrol Dial Transplant 2005 20 129 134 10.1093/ndt/gfh568 15585515 (Pubitemid 40207617)
114. Influence of gender, age and renal function on plasma adiponectin level: the Tanno and Sobetsu study. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K, Eur J Endocrinol 2005 153 91 98 10.1530/eje.1.01930 15994750 (Pubitemid 41030520)
115. Up-regulation of adiponectin, its isoforms and receptors in end-stage kidney disease. Shen YY, Charlesworth JA, Kelly JJ, Loi KW, Peake PW, Nephrol Dial Transplant 2007 22 1 171 178 17005524 (Pubitemid 46050342)
116. Adiponectin-an adipokine with unique metabolic properties. Wicek A, Adamczak M, Chudek J, Nephrol Dial Transplant 2007 22 981 988 10.1093/ndt/gfl814 17234664 (Pubitemid 46523405)
117. Serum adiponectin and renal dysfunction in men with type 2 diabetes. Lin J, Hu FB, Curhan G, Diabetes Care 2007 30 239 244 10.2337/dc06-1296 17259488 (Pubitemid 46198325)
118. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. Guan Y, J Am Soc Nephrol 2004 15 2801 2815 10.1097/01.ASN.0000139067.83419.46 15504933 (Pubitemid 41103389)
119. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. Kubota N, Terauchi Y, Kubota T, et al. J Biol Chem 2006 281 13 8748 8755 10.1074/jbc.M505649200 16431926 (Pubitemid 43847980)
120. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. Schneider CA, Ferrannini E, DeFronzo R, Schernthaner G, Yates J, Erdmann Erland, J Am Soc Nephrol 2008 19 182 187 10.1681/ASN.2007060678 18057215
121. PPAR-activating angiotensin type-1 receptor blockers induce adiponectin. Clasen R, Schupp M, Foryst-Ludwig A, et al. Hypertension 2005 46 137 143 10.1161/01.HYP.0000168046.19884.6a 15939809 (Pubitemid 40946504)
122. Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II-Infused Rats. Diep QN, Mabrouk ME, Cohn JS, Endemann D, Amiri F, Virdis A, Neves MF, Schiffrin EL, Circulation 2002 105 2296 2302 10.1161/01.CIR.0000016049.86468.23 12010913 (Pubitemid 34535341)
123. BlockaDe of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Furuhashi M, Nobuyuki Ura, Higashiura K, Murukami H, Tanaka W, Moniwa N, Yoshida D, Shiamoto K, Hypertension 2003 42 76 81 10.1161/01.HYP.0000078490.59735.6E 12796280 (Pubitemid 36842239)
124. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. Guo LL, Pan Y, Jin HM, Nephrol Dial Transpant 2009 24 1876 1883 10.1093/ndt/gfn770
125. Ghrelin and the regulation of food intake and energy balance. Hosada H, Kojima M, Kangawa K, Mol Interv 2002 2 8 494 503 10.1124/mi.2.8.494 14993401
126. Ghrelin: structure and function. Kojima M, Kangawa K, Physiol Rev 2005 85 495 522 10.1152/physrev.00012.2004 15788704 (Pubitemid 40404635)
127. Associations between plasma ghrelin and body composition in end-stage renal disease: a longitudinal study. Ayala ER, Pecoits-Filho R, Heimbrger O, Lindholm B, Nordfors L, Stenvinkel P, Nephrol Dial Transplant 2004 19 421 426 10.1093/ndt/gfg559 14736968 (Pubitemid 38195993)
128. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Pérez-Fontán M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J, Nephrol Dial Transplant 2004 19 2095 2100 10.1093/ndt/gfh313 15187192 (Pubitemid 39139643)
129. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. Wynne K, Giannitsopoulou K, Small CJ, Patterson M, Frost G, Ghatei MA, Brown EA, Bloom SR, Choi P, J Am Soc Nephrol 2005 16 2111 2118 10.1681/ASN.2005010039 15888560 (Pubitemid 41716442)
130. Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. DeBoer MD, Zhu X, Levasseur PR, et al. Endocrinology 2008 149 827 835 18039782 (Pubitemid 351159354)
131. Vitamin D physiology. Lips P, Prog Biophys Mol Biol 2006 92 4 8 10.1016/j.pbiomolbio.2006.02.016 16563471 (Pubitemid 43831956)
132. Sun, vitamin D and cardiovascular disease. Zitterman A, Gummert JF, J Photochem Photobiol B 2010 101 2 124129
133. Extra-renal 25-hydroxyvitamin D3-1-hydroxylase in human health and disease. Hewison M, Burke F, Evans KN, et al. J Steroid Biochem Mol Biol 2007 103 3-5 316 321 17368179 (Pubitemid 46420518)
134. Optimizing bone health in chronic kidney disease. Pelletier S, Chapurlat R, Maturitas 2010 65 325 333 10.1016/j.maturitas.2009.12.021 20092971
135. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Barreto DV, Barreto FC, Liabeuf S, et al. Clin J Am Soc Nephrol 2009 4 6 1128 1135 10.2215/CJN.00260109 19443628
136. Vitamin D resistance. Bouillon R, Verstuyf A, Mathieu C, Van Cromphaut S, Masuyama R, Dehaes P, Carmeliet G, Best Prac Res Clin Endocrinol Metab 2006 20 4 627 645 10.1016/j.beem.2006.09.008 (Pubitemid 44872639)
137. Vitamin D and skeletal muscle tissue and function. Ceglia L, Mol Aspects Med 2008 29 6 407 414 10.1016/j.mam.2008.07.002 18727936
138. Can Vitamin D be a potential treatment for Type 2 diabetes mellitus. Meerza D, Naseem I, Ahmed J, Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2010 4 4 245 248 10.1016/j.dsx.2010.09.001 22745922
139. Cushings syndrome, glucocorticoids and the kidney. Smets P, Meyer E, Maddens B, Daminet S, Gen Comp Endocrinol 2010 169 1 10 10.1016/j.ygcen.2010.07. 004 20655918
140. Managing dyslipidemia in chronic kidney disease. Harper CR, Jacobson TA, J Am Coll Cardiol 2008 51 2375 2384 10.1016/j.jacc.2008.03.025 18565393 (Pubitemid 351815163)
141. Fish oil and cardiovascular disease: lipids and arterial function. Nestel P, Am J Clin Nutr 2000 71 suppl 228S 231S 10617976 (Pubitemid 30046121)
142. Review of the effects of omega-3 supplementation in dialysis patients. Friedman A, Moe S, Clin J Am Soc Nephrol 2006 1 182 192 10.2215/CJN.00740805 17699207 (Pubitemid 43334212)
143. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Sijben JWC, Calder PC, Proc Nutr Soc 2007 66 237 259 10.1017/S0029665107005472 17466105 (Pubitemid 46684976)
144. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH, Am J Kidney Dis 2001 38 6 1251 1263 10.1053/ajkd.2001. 29222 11728958 (Pubitemid 34193111)
145. Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution. Holmes CJ, J Diabetes Sci Technol 2009 3 6 1472 1480 20144403
146. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Stenvinkel P, Wang K, Qureshi AR, et al. Kidney Int 2005 67 2383 2392 10.1111/j.1523-1755.2005.00345.x 15882283 (Pubitemid 41623401)
147. FGF23 in chronic kidney disease. Wahl P, Wolf M, Adv Exp Med Biol 2012 728 107 125 10.1007/978-1-4614-0887-1-8 22396166
148. Exercise in the end-stage renal disease population. Johansen KL, J Am Soc Nephrol 2007 18 1845 1854 10.1681/ASN.2007010009 17442789 (Pubitemid 46870321)